BALTIMORE, Md. (WOWO) — Millions of Americans could eventually have greater access to several popular peptide compounds after a federal advisory committee recommended moving six peptides closer to broader availability through licensed compounding pharmacies.

The U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee voted during a two-day meeting to recommend that six peptides be added to the agency’s Section 503A Bulks List, according to reporting by Fox News. If the FDA ultimately approves the recommendation, licensed compounding pharmacies would be able to prepare these substances for patients with valid prescriptions, potentially shifting access away from online sellers operating in a largely unregulated market.

The FDA has not yet made a final decision.

Peptides are short chains of amino acids that help regulate biological processes, including metabolism, growth and tissue repair, according to Cleveland Clinic. Some peptide-based treatments are already used in approved medications, including insulin and certain GLP-1 drugs used for diabetes and weight management. Other peptides have gained popularity in wellness, anti-aging and performance circles but remain under federal review.

The advisory committee reviewed seven peptides during hearings in Maryland, focusing on whether they should qualify for use by compounding pharmacies.

According to Fox News, the panel voted in favor of advancing six peptides:

• BPC-157, proposed for conditions including ulcerative colitis.
• TB-500, proposed for wound healing.
• KPV, proposed for wound healing and inflammatory conditions.
• MOTS-c, proposed for obesity and osteoporosis.
• Semax, proposed for cerebral ischemia, migraine and trigeminal neuralgia, a chronic facial pain disorder.
• Epitalon, proposed for insomnia.

The committee’s recommendation does not mean the peptides are FDA-approved treatments, and it does not guarantee that patients will immediately have access to them.

Jim LaValle, a Texas-based clinical pharmacist and chair of the International Peptide Society, testified during the hearings and told Fox News Digital that the vote represents a possible move toward bringing peptide use into a more regulated medical setting.

“This was not FDA approval, nor was it a blanket endorsement of every peptide, every use or unrestricted access,” LaValle said.

LaValle argued that tighter oversight could help address concerns about products currently marketed through online sources without the same level of quality controls required of regulated pharmacies.

“I have said throughout this process that you do not solve a quality problem by forcing the market underground,” LaValle said.

He said the committee’s recommendation could help move patients away from “research use only” products sold through unofficial channels and toward a system involving licensed providers, pharmacy oversight and quality testing.

“I was encouraged by the committee’s recommendation because it creates an opportunity to move patients away from unverified research use only (RUO), otherwise known as grey market products, and toward a more accountable medical pathway,” LaValle said.

Supporters of expanded access say peptide therapies may offer potential benefits in areas including inflammation, metabolism, tissue repair and age-related health concerns. However, some researchers and medical experts have raised concerns that evidence supporting many peptide uses remains limited and that more research is needed to determine long-term safety and effectiveness.

LaValle said any future system should include safeguards such as qualified medical providers, licensed pharmacies, validated testing standards and patient monitoring.

“The right model is access with guardrails,” LaValle told Fox News Digital, emphasizing the importance of medical supervision and tracking potential side effects.

He said he hopes the FDA will use a transparent process focused on scientific evidence and establish clear standards for peptide therapies.

“My hope is that the FDA follows the recommendation with a transparent, science-driven process; establishes clear, peptide-specific standards; and follows the guidance for approving a substance that meets the FDA’s current regulations,” LaValle said.

Those standards could include confirming the quality of both the active ingredients and finished compounded products, while creating systems to monitor adverse reactions.

“The peptide revolution is here,” LaValle said. “However, don’t expect miracles.”

He said patients should continue focusing on established health measures, including nutrition, exercise, sleep, stress management and monitoring metabolic health.

“In some cases, peptides can play an important part on the journey of performance aging and repair,” LaValle said.

He also warned that the committee’s vote does not represent an immediate change in how peptides are regulated.

“The American public should understand that nothing changed overnight,” LaValle said.

The FDA will now review the advisory committee’s recommendation before deciding whether any of the peptides will be added to the compounding list. Until then, experts advise consumers to be cautious about products marketed online as “research use only” and to discuss any peptide therapy with a licensed healthcare professional.